Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives $49.14 Consensus Target Price from Analysts

Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) have earned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $49.1429.

A number of research analysts have recently commented on the company. HC Wainwright set a $56.00 price target on Mineralys Therapeutics and gave the company a “buy” rating in a research report on Tuesday, March 10th. Stifel Nicolaus lifted their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Jefferies Financial Group reaffirmed a “hold” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Friday, March 13th. Finally, Bank of America increased their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th.

Insider Activity at Mineralys Therapeutics

In related news, CFO Adam Scott Levy sold 10,758 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.14, for a total value of $345,762.12. Following the completion of the transaction, the chief financial officer directly owned 8,638 shares of the company’s stock, valued at approximately $277,625.32. This trade represents a 55.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jon Congleton sold 16,236 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $32.62, for a total transaction of $529,618.32. Following the completion of the transaction, the chief executive officer owned 639,151 shares of the company’s stock, valued at $20,849,105.62. This represents a 2.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 363,325 shares of company stock worth $12,298,347. 25.56% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC raised its stake in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after purchasing an additional 676 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Mineralys Therapeutics by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Navalign LLC bought a new position in Mineralys Therapeutics in the 4th quarter worth about $33,000. Velan Capital Investment Management LP boosted its stake in Mineralys Therapeutics by 0.6% in the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock worth $6,659,000 after purchasing an additional 1,000 shares during the period. Finally, Royal Bank of Canada grew its holdings in Mineralys Therapeutics by 262.3% during the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

Mineralys Therapeutics Trading Down 4.5%

Mineralys Therapeutics stock opened at $23.90 on Monday. Mineralys Therapeutics has a 12 month low of $10.44 and a 12 month high of $47.65. The business’s 50 day simple moving average is $29.81 and its 200 day simple moving average is $35.71. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -10.08 and a beta of 0.57.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. As a group, equities research analysts forecast that Mineralys Therapeutics will post -4.23 earnings per share for the current fiscal year.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS for Q1–Q3 2026 and bumped its FY2026 estimate (now ($2.14)), while maintaining a “Buy” rating and $56 target — a vote of confidence that can support the stock. HC Wainwright note on MLYS
• Positive Sentiment: Company update: Mineralys reported 2025 results and said it advanced the regulatory review for its hypertension candidate (lorundrostat) — regulatory progress and clinical milestones are key upside catalysts for a clinical‑stage biotech. Mineralys reports 2025 results (MSN)
• Positive Sentiment: Institutional demand: recent 1Q filings show new/expanded positions from AQR, Goldman Sachs, Woodline and others — heavy institutional ownership (≈84%) can amplify moves and indicates investor interest. MLYS institutional holdings
• Neutral Sentiment: Analyst mix and consensus: despite several Buy ratings (6 Buys, 1 Hold, 1 Sell) the street still expects sizeable negative EPS this year (consensus ≈ -4.23), and the consensus target (~$49) remains well above the current price — signals both long‑term upside expectations and near‑term valuation risk. MarketBeat analyst summary
• Negative Sentiment: Insider selling: Director/insider David Malcom Rodman has sold multiple sizable blocks recently (including 6,348 shares on Mar 12), which can be read as near‑term selling pressure or profit‑taking. Insider trades alert
• Negative Sentiment: Offsetting estimate cuts: HC Wainwright trimmed FY2027 and FY2028 EPS forecasts slightly (and nudged Q4 2026 a touch weaker), showing some longer‑horizon uncertainty despite near‑term upgrades — these downgrades add caution for longer‑dated expectations. HC Wainwright detail

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.